Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers plus Three Novel Proprietary Tests Designed with regard to Diagnosis of Dry Eye Disease
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commercial partnership agreement with Verséa Ophthalmics, LLC, a business division associated with Verséa Holdings, Inc. (“Verséa”), one of the fastest growing U. S. healthcare companies, specialized in the sale and distribution of ocular diagnostic and therapeutic solutions.
The contract will provide Verséa with the exclusive commercial right to AXIM’s proprietary portfolio associated with point-of-care (POC) lab testing readers plus three key biomarker analysis tests designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient Dry Eye Disease and non-specific allergic conjunctivitis. The three AXIM’s key biomarker tests – the particular Ocular Immunoglobulin E (IgE) test, the Lactoferrin test, and the particular future MMP-9 test – require the collection of 0. 5 microliters in tears and provide quantitative results in under 10 minutes, an industry-leading return time.
Verséa plans to launch IgE and Lactoferrin tests at the upcoming 2022 American Academy of Ophthalmology (AAO) and Us Academy associated with Optometry (AAOPT) conferences. The MMP-9 test is anticipated to follow in the next 18-24 months.
In recent months, AXIM has been preparing for the particular scaling of production associated with its assessments in anticipation of a good agreement such as the one reached with Verséa and is now prepared to support new orders associated with the agreement and subsequent launch.
“This is an exciting day regarding AXIM, one that has been years in the making – this is the moment where we move from a development-stage biotech company to a revenue generating healthcare organization, ” said John W. Huemoeller II, Chief Executive Officer of AXIM Biotech. “Since the development of our novel ocular diagnostic tests plus subsequent success in proving their effectiveness, rather than building an internal team to commercialize the checks, we have been searching for a partner with a solid commercial infrastructure and a firm commitment in order to eye care, capable associated with bringing our tests to clinical offices on a global scale. I am more than confident that we have found that will partner in Verséa. With existing sales channels to support their human amniotic membrane therapeutics, Verséa has expressed strong assistance for our own business plus a true excitement intended for adding the technology to their expanding portfolio of health care solutions. I personally believe that together, all of us will be able to change the landscape of dry eye disease diagnosis. ”
The agreement is a good illustration of Verséa’s current commitment in order to the eye care space following its appointment associated with Dr. Rob Sambursky, MD , as their President of Corporate and of Verséa Ophthalmics , a new business division set to provide innovative solutions to get the diagnosis, treatment and management associated with ocular surface area diseases.
“We are delighted to become selected by AXIM as their unique partner for the commercialization of their innovative suite of analysis solutions, ” said Sean Fetcho, CEO and co-founder of Verséa. “With special global licensing rights in order to AXIM’s Vision Diagnostics profile, Verséa will be introducing a brand new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in discovering and quantifying a variety of biomarkers related to external ocular disorders. ”
The particular President of Verséa Ophthalmics , Dr. Sambursky, MD, explained the particular significance of the new diagnostic technology: “Mild allergic conjunctivitis is frequently confused along with dry vision, while more severe sensitive disease is frequently misdiagnosed as viral conjunctivitis; yet the appropriate clinical management plus treatments are different. The AXIM analysis technology will allow eye doctors to not only identify and differentiate clinically overlapping conditions but also drive more targeted therapeutic interventions. Having access to real-time quantitative results (a specific number) at the office visit will significantly help to confirm restorative impact, leading to overall improved personalized patient care. ”
Lactoferrin is a protein contained in tears that will protects the particular ocular surface with the antimicrobial and anti-inflammatory properties. Lower concentrations of lactoferrin have been demonstrated in patients with dried out eye, which is connected with decreased aqueous tear production. Ocular Immunoglobulin E (IgE) is a biomarker pertaining to allergies plus a key biomarker primarily associated with allergic conjunctivitis. Both tests are FDA-cleared and have dedicated Medicare CPT codes.
The particular third check, a quantitative tear Matrix Metalloproteinase 9 (MMP-9) test, is the significant advancement within the measurement from the intensity of inflammation affecting dry eye individuals. Being a quantitative check for MMP-9, this test allows for the more objective classification and management associated with dry attention disease as well as subsequent pre-surgical and post-surgical therapeutic guidance. Post-surgical complications, such because worsening symptoms of dry eye plus refractive error, may end up being mitigated simply by identifying and treating dried out eye prior to cataract and refractive surgery corneal measurements.
To learn more, please visit https://aximeye.com/ .
About AXIM® Biotechnologies
Founded within 2014, AXIM® Biotechnologies, Incorporation. (AXIM) will be a vertically integrated research and development company focused on improving the landscape for that diagnosis of ophthalmological conditions such as Dry out Eye Illness (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic testing for Dye Eye Condition. For a lot more information, please visit www.AXIMBiotech.com .
Regarding Verséa™ Ophthalmics
Verséa™ Ophthalmics, LLC, a division associated with Verséa Holdings, Inc. (“Verséa”), is 1 of the particular fastest growing U. S. healthcare companies on a mission to revolutionize eye care. It is specific in the sale plus distribution of innovative options for the particular diagnosis, treatment, and management of ocular surface diseases. To find out more, check out: www.versea.com .
The particular statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning associated with Section 27A from the Securities Act of 1933, Section 21E associated with the Investments Exchange Act of 1934 and the particular Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions plus involve a number of risks and uncertainties, many of which are usually beyond the control of Axim Biotechnologies, Incorporation. Actual results could differ materially from those projected due to there being no assurance that our analysis candidate will certainly ever be approved for use by the particular U. H. FDA or any equivalent foreign regulatory agency. Further, Axim’s eyesight care diagnostic products that are FDA cleared may not really be manufactured in large enough quantities or even that third parties along with established eyes care doctors will enter into agreements or purchase through the organization, plus even if the Company’s analysis candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to period in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reviews we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or even circumstances after the date hereof or to reflect the particular occurrence associated with unanticipated events, unless otherwise required by law.
[email protected] com
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
[email protected] com